Researchers from University College London (UCL) have warned that the rapid expansion of the UK’s aesthetic botulinum toxin sector is significantly outpacing current regulatory frameworks, raising concerns about oversight, training standards and patient safety.
In analysis published in the Aesthetic Surgery Journal Open Forum in February 2026, the UCL team examined the scale and structure of the UK’s non-surgical cosmetic market, focusing specifically on botulinum toxin injections. While botulinum toxin remains a prescription-only medicine in the UK, the researchers highlighted what they describe as a fragmented system in which prescribing is regulated but administration is not restricted to medically qualified professionals.
Practitioner numbers surge 437 percent
UCL’s study reported that there are now 19,702 practitioners delivering botulinum toxin treatments across 5,589 clinics in the UK, representing a 437 percent increase since 2023. The practitioner mix reflects a highly diverse workforce: doctors account for 28.4 percent of providers, nurses 24.8 percent, dentists 10.5 percent and allied health professionals 11.2 percent. Notably, almost one in four practitioners, 24.8 percent, are non-medical aestheticians.
Researchers noted that treatments are increasingly delivered outside traditional clinical environments, including beauty salons, spas and mobile settings. While many providers operate responsibly, the variability in training pathways and clinical governance has intensified debate around minimum qualification standards and supervision requirements.
The study also identified substantial variation in pricing. On average, doctors charged approximately £187.55 per treatment and dentists £190.69, compared with £158.32 for nurses and £148.44 for aestheticians. The authors suggested that lower pricing in non-medical settings may reflect differences in training and overhead structures, potentially influencing patient choice.
In addition, botulinum toxin provision was found to be more prevalent in socioeconomically deprived areas, where access to specialist medical practitioners may be lower but practitioner density higher. Researchers described this as an emerging access-versus-safety tension within the current regulatory framework.
Regulation under review
The findings arrive amid broader UK policy discussions about tighter oversight of aesthetic procedures. The Health and Care Act 2022 introduced powers to license non-surgical cosmetic procedures, though full implementation details remain under development.
According to the UCL researchers, more robust reform would require clearer national standards for practitioner qualifications, improved transparency in remote prescribing arrangements and stronger enforcement mechanisms. They emphasised that while most botulinum toxin treatments are delivered safely, the scale and speed of market growth now demand a more cohesive regulatory response.
